Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey

This article was originally published in The Pink Sheet Daily

Executive Summary

The Swiss drug company has set a goal of generating 60% of sales in emerging markets by 2015.

You may also be interested in...



Nycomed Expands In Turkey, Despite Tough Pharma Environment

Swiss pharmaceutical manufacturer Nycomed has acquired rights from specialty pharmaceutical company Biomeks Ilac (Biomeks) to market a portfolio of over ten pharmaceutical products in Turkey

Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop

Russia has called for half of all pharmaceuticals in the country to be produced domestically in the next decade, pledging to spend 122.9 billion rubles ($3.97 billion) to get international drug makers to shift drug production to the country and strengthen R&D collaboration

Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma

Following through on a goal to expand operations in one of the world's fastest growing markets, Nycomed AS confirmed Nov. 1 that it is beefing up its Chinese presence through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel